Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi ...

AstraZeneca Pharma India gets CDSCO approval for treating endometrial cancer in the country: Our Bureau, Bengaluru Wednesday, July 2, 2025, 15:15 Hrs [IST] AstraZeneca Pharma Indi ...

WILMINGTON, Del., September 15, 2024--Positive results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically ...

AstraZeneca Pharma India Limited on Tuesday, July 1, 2025, received approval from the Central Drugs Standard Control ...

A total of 474 participants were randomly assigned to the durvalumab group, and 474 to the placebo group (median follow-up, 31.5 months; interquartile range, 26.7 to 36.6).

The new indication allows durvalumab, in combination with carboplatin and paclitaxel, to be used as a first-line treatment ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...